title: Clinical Pharmacology and Translational Aspects of Bispecific Antibodies.
authors.affiliation: Amgen Inc., Thousand Oaks, California, USA.
authors.forename: A
authors.initials: A
authors.lastname: Trivedi
authors.affiliation: Amgen Research (Munich), Munich, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Stienen
authors.affiliation: Amgen Inc., Thousand Oaks, California, USA.
authors.forename: M
authors.initials: M
authors.lastname: Zhu
authors.affiliation: Amgen Inc., Thousand Oaks, California, USA.
authors.forename: H
authors.initials: H
authors.lastname: Li
authors.affiliation: Amgen Inc., Thousand Oaks, California, USA.
authors.forename: T
authors.initials: T
authors.lastname: Yuraszeck
authors.affiliation: Amgen Inc., Thousand Oaks, California, USA.|Current address: AbbVie Inc., North Chicago, Illinois, USA.
authors.forename: J
authors.initials: J
authors.lastname: Gibbs
authors.affiliation: Amgen Inc., Thousand Oaks, California, USA.
authors.forename: T
authors.initials: T
authors.lastname: Heath
authors.affiliation: Amgen Inc., Thousand Oaks, California, USA.
authors.forename: R
authors.initials: R
authors.lastname: Loberg
authors.affiliation: Amgen Inc., Thousand Oaks, California, USA.|Current Address: AbbVie Inc., South San Francisco, California, USA.
authors.forename: S
authors.initials: S
authors.lastname: Kasichayanula
mesh_terms: D000818:Animals; D018033:Antibodies, Bispecific / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D000076722:Drug Development / Q000379:methods*; D006801:Humans; D061214:Patient Safety; D018570:Risk Assessment; D057170:Translational Research, Biomedical / Q000379:methods*
chemical_list: D018033:Antibodies, Bispecific